• All Courts
  • Federal Courts
  • Bankruptcies
  • PTAB
  • ITC
Track Search
Export
Download All
Active Filters
Displaying 624-638 of 973 results

2431 Exhibit: EX2431 US Food Drug Administration, DrugsFDA, Oseni®

Document IPR2023-00724, No. 2431 Exhibit - EX2431 US Food Drug Administration, DrugsFDA, Oseni® (P.T.A.B. Jan. 17, 2024)

cite Cite Document
Analyze

2498 Exhibit: EX2498 Novo Nordisk, Financial report for the period 1 January 2019...

Document IPR2023-00724, No. 2498 Exhibit - EX2498 Novo Nordisk, Financial report for the period 1 January 2019 to 31 March 2019 May 3, 2019 (P.T.A.B. Jan. 17, 2024)

cite Cite Document
Analyze

2363 Exhibit: EX2363 US Food Drug Administration, DrugsFDA, Micronase®

Document IPR2023-00724, No. 2363 Exhibit - EX2363 US Food Drug Administration, DrugsFDA, Micronase® (P.T.A.B. Jan. 17, 2024)

cite Cite Document
Analyze

2389 Exhibit: EX2389 Ho, PM, Bryson, CL, and Rumsfeld, JS, Medication Adheren...

Document IPR2023-00724, No. 2389 Exhibit - EX2389 Ho, PM, Bryson, CL, and Rumsfeld, JS, Medication Adherence, Circulation, 2009 119233028 3035 (P.T.A.B. Jan. 17, 2024)

cite Cite Document
Analyze

2352 Exhibit: EX2352 Mayo Clinic, “Diabetes – Symptoms causes,” httpswwwmayoc...

Document IPR2023-00724, No. 2352 Exhibit - EX2352 Mayo Clinic, “Diabetes – Symptoms causes,” httpswwwmayoclinicorgdiseases conditionsdiabetessymptoms causessyc 20371444, last updated Sept...

cite Cite Document
Analyze

2367 Exhibit: EX2367 Sirtori, CR and Pasik, C, Re evaluation of a biguanide, metfo...

Document IPR2023-00724, No. 2367 Exhibit - EX2367 Sirtori, CR and Pasik, C, Re evaluation of a biguanide, metformin mechanism of action and tolerability, Pharmacol Res 1994 Oct Nov 303187 228 (P....

cite Cite Document
Analyze

1090 Exhibit: Exhibit 1090

Document IPR2023-00724, No. 1090 Exhibit - Exhibit 1090 (P.T.A.B. Aug. 10, 2023)

cite Cite Document
Analyze

1131 Exhibit: Exhibit 1131 Form 6K 2011

Document IPR2023-00724, No. 1131 Exhibit - Exhibit 1131 Form 6K 2011 (P.T.A.B. May. 22, 2024)

cite Cite Document
Analyze

1122 Exhibit: Exhibit 1122 ADA Standards 2023

Document IPR2023-00724, No. 1122 Exhibit - Exhibit 1122 ADA Standards 2023 (P.T.A.B. May. 22, 2024)

cite Cite Document
Analyze

1125 Exhibit: Exhibit 1125 Pi Sunyer

Document IPR2023-00724, No. 1125 Exhibit - Exhibit 1125 Pi Sunyer (P.T.A.B. May. 22, 2024)

cite Cite Document
Analyze

1097 Exhibit: Exhibit 1097 Garber 2009

Document IPR2023-00724, No. 1097 Exhibit - Exhibit 1097 Garber 2009 (P.T.A.B. May. 22, 2024)

cite Cite Document
Analyze

1129 Exhibit: Exhibit 1129 Cecil

Document IPR2023-00724, No. 1129 Exhibit - Exhibit 1129 Cecil (P.T.A.B. May. 22, 2024)

cite Cite Document
Analyze

1119 Exhibit: Exhibit 1119 Trulicity label

Document IPR2023-00724, No. 1119 Exhibit - Exhibit 1119 Trulicity label (P.T.A.B. May. 22, 2024)

cite Cite Document
Analyze

1127 Exhibit: Exhibit 1127 CLAIM CONSTRUCTION ORDER

Document IPR2023-00724, No. 1127 Exhibit - Exhibit 1127 CLAIM CONSTRUCTION ORDER (P.T.A.B. May. 22, 2024)

cite Cite Document
Analyze

1101 Exhibit: Exhibit 1101 Ozempic Orange Book

Document IPR2023-00724, No. 1101 Exhibit - Exhibit 1101 Ozempic Orange Book (P.T.A.B. May. 22, 2024)

cite Cite Document
Analyze
<< 1 2 3 4 5 ... 42 43 44 45 46 ... >>